Search

Displaying results 5911 - 5920 of 10000 in total
  1. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system.

  2. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). … Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects.

  3. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). … It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system.

  4. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

  5. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as

  6. Drug

    Arecoline

    go.drugbank.com/drugs/DB04365
    Experimental

    It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands. … An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors.

  7. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase.

  8. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. … ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.

  9. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation

  10. Drug

    Squalene

    go.drugbank.com/drugs/DB11460
    ApprovedInvestigationalVet approvedWithdrawn

    Squalene is investigated as an adjunctive cancer therapy. … It is a natural 30-carbon isoprenoid compound and intermediate metabolite in the synthesis of cholesterol. It is not susceptible to lipid peroxidation and provides skin protection.